2020 IPO
SutroVax Stock
SutroVax is a biopharmaceutical company
Sign up today and learn more about SutroVax Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About SutroVax Stock
SutroVax is a recently established biopharmaceutical company developing vaccines for infectious disease targets with an initial emphasis on best-in-class conjugate vaccines and protein-based vaccines. SutroVax is an independent company that was spun out of Sutro Biopharma with an exclusive license to Sutro Biopharma’s Xpress CF™ platforms for cell free protein synthesis and site-specific conjugation.
Funding History
| July 2015 | $22.0M |
|---|---|
| March 2017 | $4.0M |
| March 2017 | $60.0M |
| June 2018 | $85.0M |
Management
Chairman
Moncef Slaoui
Founder & CEO
Grant E. Pickering
Press
OutSourcing-Pharma.com - Jun, 12 2018
After raising $85m, SutroVax contracts Lonza to support vaccine developmentFierceBiotech - May, 25 2018
Pivotal bioVenture Partners debuts $150M China-focused biotech fundThe Pharma Letter - Mar, 7 2018
Analysts say cell-based and recombinant flu vaccines are the futurePR Newswire (press release) - Oct, 11 2017
SutroVax Appoints Veteran Vaccine Experts to Executive TeamEquityZen Recognized As:
